Absci anticipates interim 13-week ABS-201 pattern hair loss data next month as it plans mid-2027 endometriosis Phase 2 start


Earnings Call Insights: Absci (ABSI) Q3 2026

Management view

  • “Absci continues to make strides across our whole business” (Founder, CEO, President & Director Sean McClain), and “next month, we anticipate sharing interim 13-week data” from the ABS-201 Phase I/IIa HEADLINE trial in pattern hair loss, followed by “the full POC data

Seeking Alpha’s Disclaimer: This article was automatically generated by an AI tool based on content available on the Seeking Alpha website, and has not been curated or reviewed by humans. Due to inherent limitations in using AI-based tools, the accuracy, completeness, or timeliness of such articles cannot be guaranteed. This article is intended for informational purposes only. Seeking Alpha does not take account of your objectives or your financial situation and does not offer any personalized investment advice. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.



Source link

4 films that are unrecognizable when you upgrade from DVD to 4K UHD

Taylor Swift and Karlie Kloss’ Feud Involved Scooter Braun: Report

Leave a Reply

Your email address will not be published. Required fields are marked *